First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice

被引：0
|
作者：
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
ONCOLOGY-NEW YORK | 2013年 / 27卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [1] The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
    Andrews, Claire N.
    Lipton, Jeffrey
    LANCET HAEMATOLOGY, 2019, 6 (08): : E385 - E386
  • [2] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
  • [3] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (01) : 17 - 26
  • [4] Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 325 - 325
  • [5] First-Line Treatment for Patients With CML in Chronic Phase: Why Imatinib Is an Appropriate Choice
    Schiffer, Charles A.
    ONCOLOGY-NEW YORK, 2013, 27 (08): : 780 - +
  • [6] Stopping second-generation TKIs in CML
    Laneuville, Pierre
    BLOOD, 2017, 129 (07) : 805 - 806
  • [7] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, M.
    Alimena, G.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
  • [8] The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia (vol 6, pg e385, 2019)
    Andrews, C. N.
    Lipton, J.
    LANCET HAEMATOLOGY, 2020, 7 (01): : E11 - E11
  • [9] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML) (vol 28, pg 17, 2014)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (03) : 325 - 325
  • [10] First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
    Vener, Claudia
    Banzi, Rita
    Ambrogi, Federico
    Ferrero, Annalisa
    Saglio, Giuseppe
    Pravettoni, Gabriella
    Sant, Milena
    BLOOD ADVANCES, 2020, 4 (12) : 2723 - 2735
12345